MX370451B - Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi metil)-naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular. - Google Patents

Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi metil)-naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular.

Info

Publication number
MX370451B
MX370451B MX2017008591A MX2017008591A MX370451B MX 370451 B MX370451 B MX 370451B MX 2017008591 A MX2017008591 A MX 2017008591A MX 2017008591 A MX2017008591 A MX 2017008591A MX 370451 B MX370451 B MX 370451B
Authority
MX
Mexico
Prior art keywords
methyl
hydroxycarbamoyl
carbamoyloxy
naphthalen
phenyl
Prior art date
Application number
MX2017008591A
Other languages
English (en)
Inventor
Saccone Valentina
Consalvi Silvia
Lorenzo Puri Pïer
Mascagni Paolo
Original Assignee
Italfarmaco Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco Spa filed Critical Italfarmaco Spa
Publication of MX370451B publication Critical patent/MX370451B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a un método para el tratamiento de distrofia muscular que comprende administrar cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil)-naftalen- 2-il-metil]-amonio u otras sales y/o solvatos del mismo aceptables para uso farmacéutico a un paciente que necesita tal tratamiento. La invención además se refiere a un método para el tratamiento de distrofia muscular que comprende administrar cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil) -naftalen-2-il-metil)-amonio u otras sales y/o solvatos del mismo aceptables para uso farmacéutico en combinación con uno o más agentes activos antiinflamatorios adicionales a un paciente que necesita tal tratamiento.
MX2017008591A 2012-02-03 2012-02-03 Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi metil)-naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular. MX370451B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2012/000040 WO2013114413A1 (en) 2012-02-03 2012-02-03 Diethyl- [6- (4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl) - naphthalen-2-yl-methyl] -ammonium chloride for use in the treatment of muscular dystrophy

Publications (1)

Publication Number Publication Date
MX370451B true MX370451B (es) 2019-12-13

Family

ID=45992803

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014009049A MX349767B (es) 2012-02-03 2012-02-03 Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil) -naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular.
MX2017008591A MX370451B (es) 2012-02-03 2012-02-03 Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi metil)-naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014009049A MX349767B (es) 2012-02-03 2012-02-03 Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil) -naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular.

Country Status (11)

Country Link
US (2) US9421184B2 (es)
EP (3) EP3871669A1 (es)
JP (2) JP2015512869A (es)
CN (2) CN104093403A (es)
AR (1) AR089839A1 (es)
AU (1) AU2012368818B2 (es)
BR (1) BR112014018975A2 (es)
CA (1) CA2857082C (es)
HK (1) HK1200731A1 (es)
MX (2) MX349767B (es)
WO (1) WO2013114413A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITUB20155193A1 (it) * 2015-11-03 2017-05-03 Italfarmaco Spa Sospensioni orali di Givinostat fisicamente e chimicamente stabili
IT201900003281A1 (it) * 2019-03-06 2020-09-06 Chemi Spa Processo per preparare {6-[(dietilammino)metil]naftalen-2-il}metil [4-(idrossicarbamoil)fenil]carbammato ad elevata purezza
US11918570B2 (en) 2020-04-13 2024-03-05 The Research Foundation For The State University Of New York Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
ITMI20011733A1 (it) * 2001-08-07 2003-02-07 Italfarmaco Spa Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc
US7229963B2 (en) 2001-10-18 2007-06-12 United States of America as represented by the Secretary of the Department of of Health Services, National Institutes of Health Methods of using deacetylase inhibitors to promote cell differentiation and regeneration
FR2847817B1 (fr) 2002-11-28 2006-11-10 Centre Nat Rech Scient Utilisation d'un inhibiteur d'histone deacetylase pour le traitement des dystrophies musculaires
ITMI20030063A1 (it) * 2003-01-17 2004-07-18 Italfarmaco Spa Cloridrato monoidrato dell'estere (6-dietilamminometil-naftalen-2-il)metilico dell'acido (4-idrossicarbammoil-fenil)carbammico.
FR2898274B1 (fr) * 2006-03-07 2008-10-03 Sod Conseils Rech Applic Composition contenant des derives d'amidine ou de carboxamide et des steroides a titre de medicament
US8012695B2 (en) * 2007-02-14 2011-09-06 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to promoter regulation by MUC1 and KLF proteins
NZ584279A (en) * 2007-09-19 2011-11-25 4Sc Ag Novel tetrahydrofusedpyridines as histone deacetylase inhibitors
IT1396915B1 (it) 2009-10-23 2012-12-20 Italfarmaco Spa Dietil-[6-(4-idrossicarbamoil-fenil-carbamoilossimetil)-naftalen-2-il-metil]-ammonio cloruro ed altri derivati della n-idrossi-benzammide per l'uso nel trattamento di infezioni da hiv.
IT1397912B1 (it) * 2010-01-28 2013-02-04 Chemi Spa Nuovo polimorfo dell'estere 6-dietilamminometil-2-naftilico dell'acido 4-idrossicarbamoil-fenil-carbammico cloridrato.
US8217079B2 (en) * 2010-03-26 2012-07-10 Italfarmaco Spa Method for treating Philadelphia-negative myeloproliferative syndromes
WO2011127482A2 (en) * 2010-04-09 2011-10-13 The Salk Institute For Biological Studies Modulation of histone deacetylases for the treatment of metabolic disease, methods and compositions related thereto

Also Published As

Publication number Publication date
US9421184B2 (en) 2016-08-23
AU2012368818A2 (en) 2014-08-28
US20160346243A1 (en) 2016-12-01
JP2015512869A (ja) 2015-04-30
MX349767B (es) 2017-08-11
CA2857082A1 (en) 2013-08-08
HK1200731A1 (en) 2015-08-14
EP3858340A1 (en) 2021-08-04
JP2016128504A (ja) 2016-07-14
US9867799B2 (en) 2018-01-16
JP6502876B2 (ja) 2019-04-17
AU2012368818B2 (en) 2017-11-16
MX2014009049A (es) 2014-11-25
US20140370089A1 (en) 2014-12-18
EP3871669A1 (en) 2021-09-01
CN104093403A (zh) 2014-10-08
AU2012368818A1 (en) 2014-08-21
EP2809313A1 (en) 2014-12-10
CA2857082C (en) 2019-07-09
AR089839A1 (es) 2014-09-17
CN107007580A (zh) 2017-08-04
WO2013114413A1 (en) 2013-08-08
BR112014018975A2 (pt) 2018-05-08

Similar Documents

Publication Publication Date Title
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
IN2015DN03219A (es)
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
PH12015502628A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
MX2016000364A (es) Metodos para tratar o prevenir afecciones oftalmologicas.
NZ732507A (en) Improved compositions for treating muscular dystrophy
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
MX2021005317A (es) Composiciones y métodos para absorción transmucosa.
NZ602478A (en) Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
MX337614B (es) Tratamiento de lupus nefritis usando laquinimod.
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
PH12016502352A1 (en) Pharmaceutical composition
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX370451B (es) Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi metil)-naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular.
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
PH12015501538A1 (en) Topical ocular analgesic agents
GB201115977D0 (en) Neurodevelopmental disorders
MX358512B (es) Uso de (r)-7cloro-n-(quinuclidin-3-il) benzo[b] tiofeno-2-carboxamida o una sal farmacéuticamente aceptable de la misma para preparar una composición farmacéutica en el tratamiento de una disfunción cognitiva.